Intraoperative BleedingNCT07179991
DDAVP Effect by TEG6 in Cardiac Surgery
An observational study of Intraoperative Bleeding, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
Trial summary
Cardiopulmonary bypass (CPB) is a process that uses a pump that temporarily takes over the function of the heart and lungs during cardiac surgery to maintain blood circulation and oxygenation. Using CPB during cardiac surgery can result in complications with blood clotting. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intraoperative Bleeding
- What is being tested?
- Desmopressin after protamine reversal
- How many people
- 100 participants
- Where
- 1 siteCanada
- Study dates
- 1 Aug 2026to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a prospective, observational, single centre study being conducted at London Health Sciences Centre (LHSC) with adults undergoing elective cardiac surgery with cardiopulmonary bypass to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery.
Who may be able to join
- Age 18 years and above
- Undergoing elective cardiac surgery with cardiopulmonary bypass
- Able to provide informed consent
Who cannot join
- Hyponatremia
- Allergy to desmopressin or its components
- History of coronary artery disease with thrombosis
- Recent history of thromboembolic events (Stroke/TIA/DVTs)
- Severe Renal Impairment Creatinine Clearance<30 ml/min
- Inability to communicate in the English language
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
London Health Sciences Centre
London, Ontario, N6A 5A5
Satoru Fujii, 5196858500 ext. 19147, satoru.fujii@lhsc.on.ca
About this study
Official title: Desmopressin Effect on Platelet Function Assessment by Thromboelastography (TEG 6) in Cardiac Surgery
Cardiopulmonary bypass (CPB) is a process that uses a pump that temporarily takes over the function of the heart and lungs during cardiac surgery to maintain blood circulation and oxygenation. Using CPB during cardiac surgery can result in complications with blood clotting. Blood clotting is achieved when molecules in the blood, called platelets, are able to form together with the help of other clotting factors to form a clot. A drug called desmopressin (DDAVP) is used to help blood clot properly by increasing the amount of clotting factors in the blood. Several studies have shown that desmopressin has the ability to reduce the amount of blood transfusions needed for cardiac surgery patients in the postoperative period. At LHSC desmopressin is frequently requested by Cardiac Surgeons and Anesthesiologists to stop bleeding and promote blood clotting where required. A test called TEG6s platelet mapping is a blood test used to help manage the use of blood products by being able to provide information on platelet function and blood clotting activity. At the moment, there is a lack of information regarding the use of TEG6s platelet mapping to analyze the effect of desmopressin on blood clotting in cardiac surgery patients after CPB. The purpose of this study is to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery with CPB. By using TEG6s platelet mapping, this study aims to observe dynamic changes in platelet function following desmopressin administration at various time points in the perioperative and postoperative periods.
Read the detailed description
Cardiopulmonary bypass (CPB) during cardiac surgery is frequently complicated by disturbances in coagulation parameters and platelet function. Desmopressin (DDAVP) has been utilized to enhance platelet adhesion and aggregation by increasing plasma levels of von Willebrand factor (vWF) and factor VIII that plays a crucial role in blood clotting. Several studies demonstrated a positive effect of DDAVP in hemostasis (particularly in patients with qualitative platelet dysfunction), reduced blood transfusion and bleeding in the post operative period.
Viscoelastic testing, specifically TEG (Thromboelastography) platelet mapping and TEG6s and have been shown to be helpful in managing the use of blood products, fresh frozen plasma (FFP), platelets and fibrinogen, in coagulopathic patient post cardiopulmonary bypass. Desmopressin is given at a dose 0.3 micrograms/kg intravenously over 15 to 30 minutes as a standard dose in cardiac surgery, up to 20 mcg which is the United States Food and Drug Administration (US FDA) recommended dose for Hemophilia treatment and the most commonly cited dose used in cardiac surgery after cardiopulmonary bypass. The TEG6s platelet mapping shows baseline platelet function and receptor-specific platelet function and inhibition. This assessment is based on four different assays including Koalin, Activator F, ADP (Adenosine Diphosphate), AA (Arachidonic Acid). At the current time there is limited literature looking at the qualitative effect of desmopressin on platelet function using TEG6s platelet mapping analysis. The purpose of this study is to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery. By using TEG6s platelet mapping we aim to observe dynamic changes in platelet function following desmopressin administration at various time points in perioperative and postoperative periods.
Informed, written consent will be obtained prior to the start of surgery.
Participants that are enrolled in this study will have their surgery proceed according to plan and will be placed under general anesthesia using standard of care practices. Cardiopulmonary bypass will be implemented in accordance with standard of care practices. Desmopressin will be given to participants at a dose of 0.3mcg/kg, up to 20 mcg after protamine reversal at the end of cardiopulmonary bypass.
Platelet function will be assessed by TEG platelet mapping at the following points:
- T1 TEG6s: after arterial line insertion before skin incision.
- T2 TEG6s: after protamine (baseline function after CPB)
- T3 TEG6s: 30 minutes after desmopressin
- T4 TEG6s: 6 hours after (intensive care unit) ICU admission
- T5 TEG6s: 24hours after ICU admission
This will involve drawing 4 ml of blood from patients at each of the above time points (5 blood draws total), in a dark green-top (Sodium Heparin) Vacutainer® tube by the Cardiac Anesthesiologist who will be also running the test on the TEG Machine. The study team will also collect information such as participant age, biological sex, height, weight, medications, medical history, surgical details, results of preoperative and postoperative blood work, and details of their postoperative recovery.
- Conditions
- Intraoperative Bleeding
- Being tested
- Desmopressin after protamine reversal
- Keywords
- Desmopressin, Cardiopulmonary bypass
- Medical subject headings
- Blood Loss, Surgical
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Desmopressin after protamine reversalDrug
Desmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB).
Platelet function will be assessed by TEG (Thromboelastography) platelet mapping at the following points:
- T1 TEG6s: after arterial line insertion before skin incision.
- T2 TEG6s: after protamine (baseline function after CPB)
- T3 TEG6s: 30 minutes after desmopressin
- T4 TEG6s: 6 hours after (intensive care unit) ICU admission
- T5 TEG6s: 24hours after ICU admission
| Study group | Role | What they receive |
|---|---|---|
| Desmopressin after protamine reversal | Desmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB). Receives: Drug: Desmopressin after protamine reversal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in platelet function due to desmopressin administration after cardiopulmonary bypass
This will be measured by TEG6s platelet mapping.
Measured: After arterial line insertion - 24 hours after admission to the intensive care unit
Secondary outcomes (2)
Impact of desmopressin on transfusion products required
This will be measured by recording the amount of blood products required for transfusion.
Measured: After arterial line insertion - 24 hours after admission to the intensive care unit
Impact of desmopressin on chest drainage
This will be measured by recording the fluid drained from the chest of participants
Measured: After arterial line insertion - 24 hours after admission to the intensive care unit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2025
- Study start1 Aug 2026
- Primary completion1 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Intraoperative BleedingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Satoru Fujii, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Investigators
- Satoru Fujii, Principal investigator, London Health Sciences Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07179991
- Sponsor's protocol ID
- DDAVP TEG6
- Status last verified
- Sep 2026
- First submitted
- 11 Sep 2025
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology. 1992 Jul;77(1):38-46. doi: 10.1097/00000542-199207000-00007.
PubMed 1610009Ozkisacik E, Islamoglu F, Posacioglu H, Yagdi T, Basarir S, Omay SB, Ozbaran M, Buket S. Desmopressin usage in elective cardiac surgery. J Cardiovasc Surg (Torino). 2001 Dec;42(6):741-7.
PubMed 11698939Jahangirifard A, Mirtajani SB, Madadi F. Effect of Desmopressin on Bleeding After Heart Surgeries: A Narrative Review. Anesth Pain Med. 2023 Mar 10;13(2):e133894. doi: 10.5812/aapm-133894. eCollection 2023 Apr.
PubMed 37645010Wademan BH, Galvin SD. Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):360-70. doi: 10.1093/icvts/ivt491. Epub 2013 Nov 21.
PubMed 24263581Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet. 1999 Jul 10;354(9173):106-10. doi: 10.1016/S0140-6736(98)12494-7.
PubMed 10408485Agarwal S, Abdelmotieleb M. Viscoelastic testing in cardiac surgery. Transfusion. 2020 Oct;60 Suppl 6:S52-S60. doi: 10.1111/trf.16075. Epub 2020 Sep 21.
PubMed 32955756Meco M, Montisci A, Giustiniano E, Greco M, Pappalardo F, Mammana L, Panisi P, Roscitano C, Cirri S, Donatelli F, Albano G. Viscoelastic Blood Tests Use in Adult Cardiac Surgery: Meta-Analysis, Meta-Regression, and Trial Sequential Analysis. J Cardiothorac Vasc Anesth. 2020 Jan;34(1):119-127. doi: 10.1053/j.jvca.2019.06.030. Epub 2019 Jun 28.
PubMed 31445833Li C, Zhao Q, Yang K, Jiang L, Yu J. Thromboelastography or rotational thromboelastometry for bleeding management in adults undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. J Thorac Dis. 2019 Apr;11(4):1170-1181. doi: 10.21037/jtd.2019.04.39.
PubMed 31179059Jin L, Ji HW. Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery. Chin Med J (Engl). 2015 Mar 5;128(5):644-7. doi: 10.4103/0366-6999.151663.
PubMed 25698197Salmenpera M, Kuitunen A, Hynynen M, Heinonen J. Hemodynamic responses to desmopressin acetate after CABG: a double-blind trial. J Cardiothorac Vasc Anesth. 1991 Apr;5(2):146-9. doi: 10.1016/1053-0770(91)90328-q.
PubMed 1863726Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery--a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost. 1995 Oct;74(4):1064-70.
PubMed 8560415Desborough MJ, Oakland K, Brierley C, Bennett S, Doree C, Trivella M, Hopewell S, Stanworth SJ, Estcourt LJ. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev. 2017 Jul 10;7(7):CD001884. doi: 10.1002/14651858.CD001884.pub3.
PubMed 28691229Rogers AL, Allman RD, Fang X, Kindell LC, Nifong LW, Degner BC, Akhter SA. Thromboelastography-Platelet Mapping Allows Safe and Earlier Urgent Coronary Artery Bypass Grafting. Ann Thorac Surg. 2022 Apr;113(4):1119-1125. doi: 10.1016/j.athoracsur.2021.07.068. Epub 2021 Aug 24.
PubMed 34437860Sivapalan P, Back AC, Ostrowski SR, Ravn HB, Johansson PI. Transfusion requirements in elective cardiopulmonary bypass surgery patients: predictive value of Multiplate and Thromboelastography (TEG) Platelet Mapping Assay. Scand J Clin Lab Invest. 2017 Sep;77(5):345-351. doi: 10.1080/00365513.2017.1325000. Epub 2017 May 24.
PubMed 28537454Agarwal S, Johnson RI, Kirmani BH. Pre- and Post-Bypass Platelet Function Testing With Multiple Electrode Aggregometry and TEG Platelet Mapping in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2015 Oct;29(5):1272-6. doi: 10.1053/j.jvca.2015.01.028. Epub 2015 Jan 16.
PubMed 25987196
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Desmopressin Effect on Platelet Function Assessment by Thromboelastography (TEG 6) in Cardiac Surgery
- ClinicalTrials.gov ID
- NCT07179991
- Acronym / sponsor ID
- DDAVP TEG6
- Conditions
- Intraoperative Bleeding
- Keywords
- Desmopressin, Cardiopulmonary bypass
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 1 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 18 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiopulmonary bypass (CPB) is a process that uses a pump that temporarily takes over the function of the heart and lungs during cardiac surgery to maintain blood circulation and oxygenation. Using CPB during cardiac surgery can result in complications with blood clotting. Blood clotting is achieved when molecules in the blood, called platelets, are able to form together with the help of other clotting factors to form a clot. A drug called desmopressin (DDAVP) is used to help blood clot properly by increasing the amount of clotting factors in the blood. Several studies have shown that desmopressin has the ability to reduce the amount of blood transfusions needed for cardiac surgery patients in the postoperative period. At LHSC desmopressin is frequently requested by Cardiac Surgeons and Anesthesiologists to stop bleeding and promote blood clotting where required. A test called TEG6s platelet mapping is a blood test used to help manage the use of blood products by being able to provide information on platelet function and blood clotting activity. At the moment, there is a lack of information regarding the use of TEG6s platelet mapping to analyze the effect of desmopressin on blood clotting in cardiac surgery patients after CPB. The purpose of this study is to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery with CPB. By using TEG6s platelet mapping, this study aims to observe dynamic changes in platelet function following desmopressin administration at various time points in the perioperative and postoperative periods.
Detailed description
Cardiopulmonary bypass (CPB) during cardiac surgery is frequently complicated by disturbances in coagulation parameters and platelet function. Desmopressin (DDAVP) has been utilized to enhance platelet adhesion and aggregation by increasing plasma levels of von Willebrand factor (vWF) and factor VIII that plays a crucial role in blood clotting. Several studies demonstrated a positive effect of DDAVP in hemostasis (particularly in patients with qualitative platelet dysfunction), reduced blood transfusion and bleeding in the post operative period.
Viscoelastic testing, specifically TEG (Thromboelastography) platelet mapping and TEG6s and have been shown to be helpful in managing the use of blood products, fresh frozen plasma (FFP), platelets and fibrinogen, in coagulopathic patient post cardiopulmonary bypass. Desmopressin is given at a dose 0.3 micrograms/kg intravenously over 15 to 30 minutes as a standard dose in cardiac surgery, up to 20 mcg which is the United States Food and Drug Administration (US FDA) recommended dose for Hemophilia treatment and the most commonly cited dose used in cardiac surgery after cardiopulmonary bypass. The TEG6s platelet mapping shows baseline platelet function and receptor-specific platelet function and inhibition. This assessment is based on four different assays including Koalin, Activator F, ADP (Adenosine Diphosphate), AA (Arachidonic Acid). At the current time there is limited literature looking at the qualitative effect of desmopressin on platelet function using TEG6s platelet mapping analysis. The purpose of this study is to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery. By using TEG6s platelet mapping we aim to observe dynamic changes in platelet function following desmopressin administration at various time points in perioperative and postoperative periods.
Informed, written consent will be obtained prior to the start of surgery.
Participants that are enrolled in this study will have their surgery proceed according to plan and will be placed under general anesthesia using standard of care practices. Cardiopulmonary bypass will be implemented in accordance with standard of care practices. Desmopressin will be given to participants at a dose of 0.3mcg/kg, up to 20 mcg after protamine reversal at the end of cardiopulmonary bypass.
Platelet function will be assessed by TEG platelet mapping at the following points:
- T1 TEG6s: after arterial line insertion before skin incision.
- T2 TEG6s: after protamine (baseline function after CPB)
- T3 TEG6s: 30 minutes after desmopressin
- T4 TEG6s: 6 hours after (intensive care unit) ICU admission
- T5 TEG6s: 24hours after ICU admission
This will involve drawing 4 ml of blood from patients at each of the above time points (5 blood draws total), in a dark green-top (Sodium Heparin) Vacutainer® tube by the Cardiac Anesthesiologist who will be also running the test on the TEG Machine. The study team will also collect information such as participant age, biological sex, height, weight, medications, medical history, surgical details, results of preoperative and postoperative blood work, and details of their postoperative recovery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Desmopressin after protamine reversal | – | Drug: Desmopressin after protamine reversalDesmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a prospective, observational, single centre study being conducted at London Health Sciences Centre (LHSC) with adults undergoing elective cardiac surgery with cardiopulmonary bypass to investigate the dose-related effects of desmopressin on platelet function in patients undergoing cardiac surgery.
Key inclusion criteria (3 listed)
- Age 18 years and above
- Undergoing elective cardiac surgery with cardiopulmonary bypass
- Able to provide informed consent
Key exclusion criteria (6 listed)
- Hyponatremia
- Allergy to desmopressin or its components
- History of coronary artery disease with thrombosis
- Recent history of thromboembolic events (Stroke/TIA/DVTs)
- Severe Renal Impairment Creatinine Clearance<30 ml/min
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Desmopressin after protamine reversalDesmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB). Platelet function will be assessed by TEG (Thromboelastography) platelet mapping at the following points: 1. T1 TEG6s: after arterial line insertion before skin incision. 2. T2 TEG6s: after protamine (baseline function after CPB) 3. T3 TEG6s: 30 minutes after desmopressin 4. T4 TEG6s: 6 hours after (intensive care unit) ICU admission 5. T5 TEG6s: 24hours after ICU admission | Drug | Desmopressin after protamine reversal |
Primary outcome
Change in platelet function due to desmopressin administration after cardiopulmonary bypass
Time frame: After arterial line insertion - 24 hours after admission to the intensive care unit
This will be measured by TEG6s platelet mapping.
2 secondary outcomes
Impact of desmopressin on transfusion products required
Time frame: After arterial line insertion - 24 hours after admission to the intensive care unit
Impact of desmopressin on chest drainage
Time frame: After arterial line insertion - 24 hours after admission to the intensive care unit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- Background: PubMed 1610009Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology. 1992 Jul;77(1):38-46. doi: 10.1097/00000542-199207000-00007.
- Background: PubMed 11698939Ozkisacik E, Islamoglu F, Posacioglu H, Yagdi T, Basarir S, Omay SB, Ozbaran M, Buket S. Desmopressin usage in elective cardiac surgery. J Cardiovasc Surg (Torino). 2001 Dec;42(6):741-7.
- Background: PubMed 37645010Jahangirifard A, Mirtajani SB, Madadi F. Effect of Desmopressin on Bleeding After Heart Surgeries: A Narrative Review. Anesth Pain Med. 2023 Mar 10;13(2):e133894. doi: 10.5812/aapm-133894. eCollection 2023 Apr.
- Background: PubMed 24263581Wademan BH, Galvin SD. Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):360-70. doi: 10.1093/icvts/ivt491. Epub 2013 Nov 21.
- Background: PubMed 10408485Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet. 1999 Jul 10;354(9173):106-10. doi: 10.1016/S0140-6736(98)12494-7.
- Background: PubMed 32955756Agarwal S, Abdelmotieleb M. Viscoelastic testing in cardiac surgery. Transfusion. 2020 Oct;60 Suppl 6:S52-S60. doi: 10.1111/trf.16075. Epub 2020 Sep 21.
- Background: PubMed 31445833Meco M, Montisci A, Giustiniano E, Greco M, Pappalardo F, Mammana L, Panisi P, Roscitano C, Cirri S, Donatelli F, Albano G. Viscoelastic Blood Tests Use in Adult Cardiac Surgery: Meta-Analysis, Meta-Regression, and Trial Sequential Analysis. J Cardiothorac Vasc Anesth. 2020 Jan;34(1):119-127. doi: 10.1053/j.jvca.2019.06.030. Epub 2019 Jun 28.
- Background: PubMed 31179059Li C, Zhao Q, Yang K, Jiang L, Yu J. Thromboelastography or rotational thromboelastometry for bleeding management in adults undergoing cardiac surgery: a systematic review with meta-analysis and trial sequential analysis. J Thorac Dis. 2019 Apr;11(4):1170-1181. doi: 10.21037/jtd.2019.04.39.
- Background: PubMed 25698197Jin L, Ji HW. Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery. Chin Med J (Engl). 2015 Mar 5;128(5):644-7. doi: 10.4103/0366-6999.151663.
- Background: PubMed 1863726Salmenpera M, Kuitunen A, Hynynen M, Heinonen J. Hemodynamic responses to desmopressin acetate after CABG: a double-blind trial. J Cardiothorac Vasc Anesth. 1991 Apr;5(2):146-9. doi: 10.1016/1053-0770(91)90328-q.
- Background: PubMed 8560415Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery--a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost. 1995 Oct;74(4):1064-70.
- Background: PubMed 28691229Desborough MJ, Oakland K, Brierley C, Bennett S, Doree C, Trivella M, Hopewell S, Stanworth SJ, Estcourt LJ. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev. 2017 Jul 10;7(7):CD001884. doi: 10.1002/14651858.CD001884.pub3.
- Individual participant dataSharing planned: No
Related trials for Intraoperative Bleeding
Active, not recruitingObservational study
Safe and Timely Antithrombotic Removal (STAR) Registry
Hemorrhage, Surgical, Hemorrhage Postoperative
Not yet recruitingObservational study
Effect of Methotrexate on Blood Loss During Laparoscopic Management of CS Scar Pregnancy
Cesarean Scar Pregnancy
Active, not recruiting
Hemoglobin Levels for Blood Transfusions During and After Surgery
Blood Transfusion, Surgery
Enrolling by invitationObservational study
Clinical Validation of a Blood Loss Monitoring System
Intraoperative Blood Loss
RecruitingPhase 3
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
Blood Loss, Surgical, Coagulation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Satoru Fujii principal investigator
London Health Sciences Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intraoperative Bleeding, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Satoru Fujii (5196858500 ext. 19147, Satoru.Fujii@lhsc.on.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in platelet function due to desmopressin administration after cardiopulmonary bypass (time frame: After arterial line insertion - 24 hours after admission to the intensive care unit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07179991, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.